<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01927939</url>
  </required_header>
  <id_info>
    <org_study_id>201207002MIB</org_study_id>
    <nct_id>NCT01927939</nct_id>
  </id_info>
  <brief_title>18F-FDG PET Metabolic Phenotype in Evaluating Therapeutic Response for Breast Cancer Patients With Bone Metastases.</brief_title>
  <official_title>The Effectiveness of 18F-FDG PET Metabolic Phenotype in Evaluating Therapeutic Response for Breast Cancer Patients With Bone Metastases.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Taiwan University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to evaluate the effectiveness of 18F-FDG PET in following up of metastastic
      bone lesions and in predicting outcome for breast cancer patients after therapy.

      Primary outcome: Using 18F-FDG uptake to evaluate the metastatic bone status after treatment.
      The PET results will be compared with the results in Tc-99m MDP bone scintigraphy.

      Secondary outcome: Evaluate the relationship between the 18F-FDG uptake of the metastatic
      bone lesions and (1) breast cancer related tumor marker, (2) patients' survival.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: Although 99mTc MDP bone scintigraphy is a sensitive tool for screening metastatic
      bone status, it is not a satisfactory imaging modality in evaluating residual disease after
      therapy. 18F-FDG PET has been an effective imaging tool for many malignancies including
      breast cancer, not only in diagnosis and staging, but also in monitoring response and
      following up disease status after therapy.

      Purpose: This study is to evaluate the effectiveness of 18F-FDG PET in following up of
      metastastic bone lesions and in predicting outcome for breast cancer patients after therapy.

      Method: Breast cancer patients with bone metastases, age 20-90 year-old, will be included in
      this study.

      Primary outcome: Using 18F-FDG uptake to evaluate the metastatic bone status after treatment.
      The PET results will be compared with the results in Tc-99m MDP bone scintigraphy.

      Secondary outcome: Evaluate the relationship between the 18F-FDG uptake of the metastatic
      bone lesions and (1) breast cancer related tumor marker, (2) patients' survival.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2012</start_date>
  <completion_date type="Anticipated">August 2014</completion_date>
  <primary_completion_date type="Anticipated">August 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The uptake of 18F-FDG PET.</measure>
    <time_frame>2 hours</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Breast Cancer</condition>
  <condition>18F-FDG PET</condition>
  <arm_group>
    <arm_group_label>Histological proven breast cancer with bone lesion</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Histological proven breast cancer, with known metastatic bone lesion(s)
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Ageï¼š20-90 years old

          2. Histological proven breast cancer, with known metastatic bone lesion(s)

          3. written informed consent signed

        Exclusion Criteria:

          1. pregnant or intend to be pregnant

          2. other malignancies known
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yen Ruoh Fang, M.D.,Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Taiwan University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yen Ruoh Fang, M.D.,Ph.D.</last_name>
    <phone>886-2-23123456</phone>
    <phone_ext>65581</phone_ext>
    <email>rfyen@ntu.edu.tw</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yen Ruoh Fang, M.D., Ph.D.</last_name>
      <phone>886-2-23123456</phone>
      <phone_ext>65581</phone_ext>
      <email>rfyen@ntu.edu.tw</email>
    </contact>
    <investigator>
      <last_name>Yen Ruoh Fang, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <reference>
    <citation>Solomayer EF, Diel IJ, Meyberg GC, Gollan C, Bastert G. Metastatic breast cancer: clinical course, prognosis and therapy related to the first site of metastasis. Breast Cancer Res Treat. 2000 Feb;59(3):271-8.</citation>
    <PMID>10832597</PMID>
  </reference>
  <reference>
    <citation>Roberts CC, Daffner RH, Weissman BN, Bancroft L, Bennett DL, Blebea JS, Bruno MA, Fries IB, Germano IM, Holly L, Jacobson JA, Luchs JS, Morrison WB, Olson JJ, Payne WK, Resnik CS, Schweitzer ME, Seeger LL, Taljanovic M, Wise JN, Lutz ST. ACR appropriateness criteria on metastatic bone disease. J Am Coll Radiol. 2010 Jun;7(6):400-9. doi: 10.1016/j.jacr.2010.02.015. Review. Erratum in: J Am Coll Radiol. 2010 Sep;7(9):e1.</citation>
    <PMID>20522392</PMID>
  </reference>
  <reference>
    <citation>Houssami N, Costelloe CM. Imaging bone metastases in breast cancer: evidence on comparative test accuracy. Ann Oncol. 2012 Apr;23(4):834-43. doi: 10.1093/annonc/mdr397. Epub 2011 Sep 6. Review.</citation>
    <PMID>21896542</PMID>
  </reference>
  <reference>
    <citation>Vassiliou V, Andreopoulos D, Frangos S, Tselis N, Giannopoulou E, Lutz S. Bone metastases: assessment of therapeutic response through radiological and nuclear medicine imaging modalities. Clin Oncol (R Coll Radiol). 2011 Nov;23(9):632-45. doi: 10.1016/j.clon.2011.03.010. Epub 2011 Apr 29. Review.</citation>
    <PMID>21530193</PMID>
  </reference>
  <reference>
    <citation>Galasko CS. Diagnosis of skeletal metastases and assessment of response to treatment. Clin Orthop Relat Res. 1995 Mar;(312):64-75. Review.</citation>
    <PMID>7634619</PMID>
  </reference>
  <reference>
    <citation>Cook GJ, Fogelman I. The role of nuclear medicine in monitoring treatment in skeletal malignancy. Semin Nucl Med. 2001 Jul;31(3):206-11. Review.</citation>
    <PMID>11430527</PMID>
  </reference>
  <reference>
    <citation>Vogel CL, Schoenfelder J, Shemano I, Hayes DF, Gams RA. Worsening bone scan in the evaluation of antitumor response during hormonal therapy of breast cancer. J Clin Oncol. 1995 May;13(5):1123-8.</citation>
    <PMID>7537797</PMID>
  </reference>
  <reference>
    <citation>Rossleigh MA, Lovegrove FT, Reynolds PM, Byrne MJ, Whitney BP. The assessment of response to therapy of bone metastases in breast cancer. Aust N Z J Med. 1984 Feb;14(1):19-22.</citation>
    <PMID>6235799</PMID>
  </reference>
  <reference>
    <citation>Mitsudomi T, Kosaka T, Endoh H, Horio Y, Hida T, Mori S, Hatooka S, Shinoda M, Takahashi T, Yatabe Y. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol. 2005 Apr 10;23(11):2513-20. Epub 2005 Feb 28.</citation>
    <PMID>15738541</PMID>
  </reference>
  <reference>
    <citation>Tateishi U, Gamez C, Dawood S, Yeung HW, Cristofanilli M, Macapinlac HA. Bone metastases in patients with metastatic breast cancer: morphologic and metabolic monitoring of response to systemic therapy with integrated PET/CT. Radiology. 2008 Apr;247(1):189-96. doi: 10.1148/radiol.2471070567.</citation>
    <PMID>18372468</PMID>
  </reference>
  <reference>
    <citation>Du Y, Cullum I, Illidge TM, Ell PJ. Fusion of metabolic function and morphology: sequential [18F]fluorodeoxyglucose positron-emission tomography/computed tomography studies yield new insights into the natural history of bone metastases in breast cancer. J Clin Oncol. 2007 Aug 10;25(23):3440-7. Epub 2007 Jun 25.</citation>
    <PMID>17592153</PMID>
  </reference>
  <reference>
    <citation>Israel O, Goldberg A, Nachtigal A, Militianu D, Bar-Shalom R, Keidar Z, Fogelman I. FDG-PET and CT patterns of bone metastases and their relationship to previously administered anti-cancer therapy. Eur J Nucl Med Mol Imaging. 2006 Nov;33(11):1280-4. Epub 2006 Jun 22.</citation>
    <PMID>16791597</PMID>
  </reference>
  <reference>
    <citation>De Giorgi U, Mego M, Rohren EM, Liu P, Handy BC, Reuben JM, Macapinlac HA, Hortobagyi GN, Cristofanilli M, Ueno NT. 18F-FDG PET/CT findings and circulating tumor cell counts in the monitoring of systemic therapies for bone metastases from breast cancer. J Nucl Med. 2010 Aug;51(8):1213-8. doi: 10.2967/jnumed.110.076455. Epub 2010 Jul 21.</citation>
    <PMID>20660382</PMID>
  </reference>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 16, 2013</study_first_submitted>
  <study_first_submitted_qc>August 20, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 23, 2013</study_first_posted>
  <last_update_submitted>April 13, 2014</last_update_submitted>
  <last_update_submitted_qc>April 13, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 15, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast cancer; bone metastases; 18F-FDG PET; 99mTc bone scintigraphy; therapy response monitoring; prognosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluorodeoxyglucose F18</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

